1. Home
  2. SMX vs NXTC Comparison

SMX vs NXTC Comparison

Compare SMX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SMX (Security Matters) Public Limited Company

SMX

SMX (Security Matters) Public Limited Company

HOLD

Current Price

$8.30

Market Cap

18.8M

Sector

Technology

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$5.14

Market Cap

17.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMX
NXTC
Founded
N/A
2015
Country
Ireland
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.8M
17.3M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
SMX
NXTC
Price
$8.30
$5.14
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $23.00
AVG Volume (30 Days)
34.1K
★ 105.2K
Earning Date
04-23-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$1.55
52 Week High
$490.00
$15.74

Technical Indicators

Market Signals
Indicator
SMX
NXTC
Relative Strength Index (RSI) 25.51 40.19
Support Level $7.19 $3.98
Resistance Level $18.98 $8.68
Average True Range (ATR) 1.83 0.87
MACD -1.03 -0.26
Stochastic Oscillator 4.62 12.38

Price Performance

Historical Comparison
SMX
NXTC

About SMX SMX (Security Matters) Public Limited Company

SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: